



SEP 25/26
2018

www.apsmaastricht.com

**11th Meeting of the European Forum on
Antiphospholipid Antibodies**
Maastricht, The Netherlands



Dear members of the Forum,

Our team is thrilled to welcome you to the *11th Meeting of the European Forum on Antiphospholipid Antibodies!* This Forum meeting provides an excellent opportunity for European clinicians and scientists involved in the field of the antiphospholipid syndrome to meet and strengthen current or future collaborations.

Maastricht is known in the Netherlands and beyond for its lively squares, narrow streets, and historical buildings. We are very proud to present the venue of the Forum meeting, the 'Sint-Lambertuskerk', a monumental church built around 1914 in Maastricht and named after the Maastricht-born Saint Lambert.

We are delighted to invite you to our networking evening at Slavante, including a walk to the spectacular view point over the Enci limestone quarry.

Also on behalf of the organizing committee, we wish you an enjoyable and fruitful Forum Meeting,

Sincerely yours,

Prof. Denis Wahl, Dr. Bas de Laat, Prof. Flip de Groot and Dr. Hilde Kelchtermans

11TH MEETING OF THE EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES

Sint Lambertus Church, Maastricht, the Netherlands

TUESDAY, SEPTEMBER 25

8.00 REGISTRATION AND WELCOME COFFEE

8.30 INTRODUCTION

Denis Wahl (France), president European Forum on Antiphospholipid Antibodies
Bas de Laat (the Netherlands), congress president
Hilde Kelchtermans (the Netherlands), co-organizer

8.45-10.30 SCIENTIFIC SESSION I: SEROLOGY OF APS

CHAIRS

Bas de Laat (the Netherlands) & Denis Wahl (France)

8.45-9.15 **KEY NOTE LECTURE: Focus on new tests and techniques**
Katrien Devreese (Belgium)

9.15-9.30 Savino Sciascia (Italy): Risk stratification and scoring system models in APS

9.30-10.00 Current criteria: The need for standardization of assays and reliability of aPL results

9.30-9.45 Maria Efthymiou (United Kingdom): LAC results APS ACTION

9.45-10.00 Savino Sciascia (Italy): aPL results APS ACTION

10.00-10.15 Walid Chayouâ (the Netherlands): Is there an added value of IgM: results from a multicenter study

10.15-10.30 Rolf Urbanus (the Netherlands): Unraveling the lupus anticoagulant paradox: evidence for an important role for FV

10.30-11.00 COFFEE BREAK: EXHIBITION AREA AND POSTER PRESENTATION

11.00-12.45 SCIENTIFIC SESSION I: ABSTRACT PRESENTATIONS

CHAIRS

Hilde Kelchtermans (the Netherlands) & Katrien Devreese (Belgium)

11.00-11.15 Pieter De Kesel (Belgium): Does DOAC-Stop® eliminate the effect of DOAC on lupus anticoagulant testing?

11.15-11.30 Pieter De Kesel (Belgium): Evaluation of the effect of unfractionated heparin, enoxaparin and danaparoid on lupus anticoagulant testing

11.30-11.45 Oscar Cabrera-Marante (Spain): Incidence of thromboembolic events in asymptomatic carriers of IgA anti-b2glycoprotein-I antibodies: a 5 year follow-up

11.45-12.00 Manuel Serrano (Spain): Anti-b2glycoprotein I antibodies of the IgA isotype recognize epitopes in domain 3, 4 and 5 that are located in the same lateral zone of the molecule

- 12.00-12.15 Ariela Hoxha (Italy): IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers
- 12.15-12.30 Antonio Serrano (Spain): The determination of non-criteria antiphospholipid antibodies makes it possible to relate APS to over one third of patients with ischemic stroke
- 12.30-12.45 Jose Omar Latino (Argentina): What is the best time to assess the antiphospholipid antibodies profile to better predict the obstetric outcome in antiphospholipid syndrome patients?
- 12.45-13.00 LECTURE: Patient out of the comfort zone**
Sander Otter (the Netherlands); Patient organization NVLE
- 13.00-14.00 LUNCH: EXHIBITION AREA AND POSTER PRESENTATION**
- 14.00-16.10 SCIENTIFIC SESSION II: CLINICAL FEATURES AND TREATMENT OF APS**
CHAIRS
Pier-Luigi Meroni (Italy) & Ricard Cervera (Spain)
- 14.00-14.30 **KEY NOTE LECTURE: Antiphospholipid Syndrome: It's Far More Than You Think**
Richard Furie (USA)
- 14.30-14.50 Ricard Cervera (Spain): Pitfalls in the organization of an APS multicenter study
- 14.50-15.05 Hannah Cohen (United Kingdom): Update on the RISAPS study (Rivaroxaban for Stroke Patients with APS)
- 15.05-15.20 Stéphane Zuily (France): Proposal for the creation of a European registry on DOACs use in APS
- 15.20-15.45 Angela Tincani (Italy): The possible role of APL European Forum in the ERN network: towards a European APS registry
- 15.45-16.00 Arsene Mekinian (France): A multicenter study to determine obstetrical outcome and treatments during pregnancy in seronegative primary APS
- 16.00-16.10 Cristina Belizna (France): First results on the retrospective part of the Hibiscus Study
- 16.10-16.40 COFFEE BREAK: EXHIBITION AREA AND POSTER PRESENTATION**
- 16.40-17.10 SCIENTIFIC SESSION II: CLINICAL FEATURES AND TREATMENT OF APS (continued)**
CHAIRS
Rolf Urbanus (the Netherlands) & Elisabet Svenungsson (Sweden)
- 16.40-16.55 Massimo Radin (Italy): Withdrawing anticoagulation when antiphospholipid antibodies turn negative: the role of the laboratory
- 16.55-17.10 Savino Sciascia (Italy): Therapeutic options when antiphospholipid antibodies turn negative

17.10-17.50 SCIENTIFIC SESSION II: ABSTRACT PRESENTATIONS

17.10-17.25 Virginie Dufrost (France): Use of direct oral anticoagulant in antiphospholipid syndrome: systematic review of literature

17.25-17-40 Manuel Serrano (Spain): Immune complexes of b2glycoprotein I in patients with IgA antiphospholipid antibodies identify patients with elevated risk of early mortality after heart transplantation

17.40-17.50 Nathalie Noirclerc (France): Heart valve disease in antiphospholipid syndrome: clinical and laboratory associations and risk factors for disease progression

18.00 LEAVE BY BUS TO SOCIAL EVENT

18.00-23.00 CONGRESS DINNER AND SOCIAL EVENT

WEDNESDAY, SEPTEMBER 26

8.00-9.10 SCIENTIFIC SESSION II: ABSTRACT PRESENTATIONS (continued)

CHAIRS

Maarten Limper (the Netherlands) & Vittorio Pengo (Italy)

- 8.00-8.10 Carlos Ramirez (USA): Evaluation of a novel multi-analyte assay for the detection of autoantibodies in the diagnosis of antiphospholipid syndrome
- 8.10-8.20 Irene Cecchi (Italy): A validation study of the global antiphospholipid syndrome score (GAPSS) in women with systemic lupus erythematosus and pregnancy morbidity
- 8.20-8.30 Daniel E. Pleguezuelo (Spain): Anti-phosphatidyl-serine/prothrombin IgG and IgM antibodies in unexplained obstetric morbidity
- 8.30-8.40 Ljudmila Stojanovich (Serbia): Presence of immune complexes of IgG/IgM bound to b2glycoprotein I is associated with non-criteria manifestations in antiphospholipid syndrome
- 8.40-8.50 Enrico Fuzzi (Sweden): Antiphospholipid antibodies in SLE define a subset of patients with hematological abnormalities and greater damage accrual
- 8.50-9.00 Tatiana Lisitsyna (Russia): Mental disorders in secondary antiphospholipid syndrome patients
- 9.00-9.10 Irene Cecchi (Italy): Is it time for biologic therapy in antiphospholipid syndrome?

9.15-10.55 SCIENTIFIC SESSION III: PATHOPHYSIOLOGY OF APS

CHAIRS

Flip de Groot (the Netherlands) & Stéphane Zuily (France)

- 9.15-9.45 **KEY NOTE LECTURE: Updating of APS pathophysiology: does it impact on our clinical management?**
Pier-Luigi Meroni (Italy)
- 9.45-10.10 Karl Lackner (Germany): Antiphospholipid antibody-induced cellular responses depend on epitope specificity
- 10.10-10.25 Stéphane Zuily (France): Is APS a thrombophilia or vasculopathy?
- 10.25-10.40 Vittorio Pengo (Italy): The role of platelets and thrombocytopenia in APS
- 10.40-10.55 Elisabet Svenungsson (Sweden): Microparticles in APS
- 10.55-11.25 COFFEE BREAK**
- 11.25-11.45 **KEY NOTE LECTURE: Lipids in APS**
Coen Hemker (the Netherlands)

11.45-12.45 SCIENTIFIC SESSION III: ABSTRACT PRESENTATIONS

CHAIRS

Hannah Cohen (United Kingdom) & Walid Chayouâ (the Netherlands)

- 11.45-12.00 Claudia Grossi (Italy): New insight into antiphospholipid syndrome: antibodies to b2glycoprotein I-domain V fail to induce thrombi in rats
- 12.00-12.15 Paola Adele Lonati (Italy): Complement activation in APS: evaluation of platelet-bound C4d in *ex-vivo* and *in-vitro* studies
- 12.15-12.30 Natalie Sippl (Sweden): Characterization of b2-glycoprotein I specific B cells from patients with the antiphospholipid syndrome
- 12.30-12.45 Thomas Moulinet (France): Predictive value of thrombocytopenia in antiphospholipid syndrome

13.00-14.00 SYMPOSIUM SUPPORTED BY Inova Diagnostics, Inc: Novel biomarkers for APS: Opportunities for improving diagnosis and beyond (*with lunch box*)MODERATOR *Vittorio Pengo (Italy)*

Cecilia Beatrice Chighizola: Beyond thrombosis: Anti-b2GPI domain 1 antibodies identify late pregnancy morbidity in APS

Savino Sciascia: Reliability of lupus anticoagulant and anti-phosphatidylserine/prothrombin antibodies: impact on the clinical management of APS patients

Ariela Hoxha: Diagnostic value of novel biomarkers for predicting clinical complications on anti-phospholipid antibody asymptomatic patients for APS

14.00 CLOSING REMARKS

Bas de Laat (the Netherlands)

POSTER PRESENTATIONS

- 1 Valentina Canti (Italy): Hydrochloroquine during pregnancy in a cohort of antiphospholipid syndrome patients: a pilot study
- 2 Angela Carrasco (Spain): Antiphospholipid autoantibodies profile and different antiphospholipid syndrome manifestations
- 3 Cecilia Chighizola (Italy): How effective is treatment with low dose aspirin and low molecular weight heparin in pregnant women with criteria antiphospholipid antibodies?
- 4 Aleksandra Djokovic (Serbia): Is there a link between antiphospholipid antibodies profile and subclinical atherosclerosis in patients with antiphospholipid syndrome?
- 5 Theo Ferreira (France): Annexin-A5 resistance and non-criteria antibodies: new tools to diagnose seronegative antiphospholipid syndrome
- 6 Ciprian Jurcut (Romania): Cardiovascular risk scores in patients with antiphospholipid syndrome: which is the best predictor?
- 7 Ciprian Jurcut (Romania): Traditional and non-criteria antiphospholipid antibodies: how strong are they correlated?
- 8 Beata Sarecka-Hujar (Poland): Relation between 4G/5G polymorphism in *PAI-1* gene and thrombosis in primary antiphospholipid syndrome - meta-analysis
- 9 Maria Satybaldyeva (Russia): Risk factors of thrombosis and bleedings in patients with antiphospholipid syndrome using dabigatran etexilate
- 10 Nataliya Seredavkina (Russia): Global hemostasis assay (thrombodynamics) in real clinical practice of rheumatologist (preliminary results)
- 11 Raquel Diaz Simon (Spain): The inclusion of aPL screening in the diagnosis study of patients with a first venous thromboembolic event would identify primary APS in one third of them
- 12 Natasa Stanisavljevic (Serbia): Oxidative stress markers are one of the major factors responsible for endothelial dysfunction in antiphospholipid syndrome patients
- 13 Dongmei Yin (the Netherlands): The role of anti-domain I antibodies in the antiphospholipid syndrome: a multi-center study
- 14 Marie Desnoyers (France): HRQoL impairment in antiphospholipid syndrome
- 15 Stéphane Zuily (France): Impact of antiphospholipid syndrome ebook on medical students' improvement of knowledge: an international randomized controlled study
- 16 Angela Tincani (Italy): Epidemiology of vascular primary antiphospholipid syndrome

ORGANIZATION COMMITTEE

Bas de Laat

Hilde Kelchtermans

Philip de Groot

Rolf Urbanus

Romy Kremers

Joost Meyers

Maarten Limper

Tessa Peters

Iris Thuis

INTERNATIONAL STEERING COMMITTEE

Pier Luigi Meroni

Vittorio Pengo

Amelia Ruffatti

Munther Khamashta

Yehuda Shoenfeld

Angela Tincani

Jakub Swadzba

Jacek Musial

Ricard Cervera

Denis Wahl

Stéphane Zuilly

Hannah Cohen

Katrien Devreese

Maria Laura Bertolaccini

DUTCH SCIENTIFIC COMMITTEE

Coen Hemker

Walid Chayouâ

Hugo ten Cate

Rolf Urbanus

Bas de Laat

Philip de Groot

Romy Kremers

Hilde Kelchtermans

Katrien Devreese

We wish to **thank** the following scientific/industry partners
for their support at the APS Forum meeting:



Knowledge crossing borders

